- Home
- VITL vs VSTM Comparison
VITL vs VSTM Comparison
Compare VITL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VITL | VSTM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.6M | 470.7M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | VITL | VSTM |
|---|---|---|
| Price | $8.24 | $4.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $32.00 | $16.50 |
| AVG Volume (30 Days) | ★ 3.8M | 2.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $759,444,000.00 | $30,914,000.00 |
| Revenue This Year | $19.72 | $282.64 |
| Revenue Next Year | $17.02 | $72.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 209.14 |
| 52 Week Low | $7.95 | $4.01 |
| 52 Week High | $53.13 | $11.25 |
Technical Indicators
Market Signals| Indicator | VITL | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 24.77 | 36.82 |
| Support Level | N/A | N/A |
| Resistance Level | $14.12 | $6.79 |
| Average True Range (ATR) | 0.95 | 0.36 |
| MACD | -0.33 | -0.13 |
| Stochastic Oscillator | 4.70 | 18.32 |
Price Performance
Historical ComparisonAbout VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.